Since recombinant IGF-1 has been synthesized, it has been used clinically in replacement therapy in patients with primary growth hormone-resistance (Laron syndrome) where IGF-1 is not synthesized (Laron, 1999). Here, IGF1 is linked to Laron syndrome.